Yazar "Lugaresi, Alessandra" için listeleme
-
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Lorscheider, Johannes; Jokubaitis, Vilija G.; Spelman, Tim; Izquierdo, Guillermo; Lugaresi, Alessandra; Havrdova, Eva; Granella, Franco (Lippincott Williams & Wilkins, 2017)Objective: To investigate the effect of disease-modifying treatment on short-term disability outcomes in secondary progressive multiple sclerosis (SPMS). Methods: Using MSBase, an international cohort study, we previously ... -
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis
Hughes, Jordana; Jokubaitis, Vilija; Lugaresi, Alessandra; Hupperts, Raymond; Izquierdo, Guillermo; Prat, Alexandre; Spitaleri, Daniele (Amer Medical Assoc, 2018)IMPORTANCE The role of inflammatory disease activity as a determinant of disability in progressive-onset multiple sclerosis (MS) remains contested. OBJECTIVE To examine the association of superimposed relapses in ... -
A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
Spelman, Timothy; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Lugaresi, Alessandra; Izquierdo, Guillermo; Butzkueven, Helmut (Lippincott Williams & Wilkins, 2018)… -
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
Warrender-Sparkes, Matthew; Spelman, Tim; Izquierdo, Guillermo; Trojano, Maria; Lugaresi, Alessandra; Grand'Maison, Francois; Van Pesch, Vincent (Sage Publications Ltd, 2016)Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis ... -
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis
Signori, Alessio; Izquierdo, Guillermo; Lugaresi, Alessandra; Hupperts, Raymond; Grand'Maison, Francois; Sola, Patrizia; Slee, Mark (Sage Publications Ltd, 2018)Background: Several natural history studies on primary progressive multiple sclerosis (PPMS) patients detected a consistent heterogeneity in the rate of disability accumulation. Objectives: To identify subgroups of PPMS ... -
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod
Fragoso, Yara Dadalti; Spelman, Tim; Boz, Cavit; Alroughani, Raed; Lugaresi, Alessandra; Vucic, Steve; Haartsen, Jodi (Elsevier Sci Ltd, 2018)Background: Fingolimod is an efficient and safe drug for treating relapsing-remitting multiple sclerosis (RRMS). In vivo, fingolimod is phosphorylated and binds to "sphingosine-1-phosphate"(S1P) receptors that are expressed ... -
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice
Spelman, Tim; Meyniel, Claire; Ignacio Rojas, Juan; Lugaresi, Alessandra; Izquierdo, Guillermo; Grand'Maison, Francois; Kalincik, Tomas (Sage Publications Ltd, 2017)Background: Characteristics at clinically isolated syndrome (CIS) examination assist in identification of patient at highest risk of early second attack and could benefit the most from early disease-modifying drugs (DMDs). ... -
Reply to: Comment on YD Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]
Fragoso, Yara Dadalti; Brooks, Joseph Bruno B.; Spelman, Tim; Boz, Cavit; Alroughani, Raed; Lugaresi, Alessandra; Haartsen, Jodi (Elsevier Sci Ltd, 2018)… -
Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Kalincik, Tomas; Horakova, Dana; Spelman, Tim; Jokubaitis, Vilija; Trojano, Maria; Lugaresi, Alessandra; Bergamaschi, Roberto (Wiley, 2015)ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly ...
